Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers
More and more colorectal surgeons believe that surgical resections of hepatic metastases
from colorectal cancer is the only chance for cure of patients. The five-year survival for
patients with hepatic metastasis from colorectal cancer after surgical resection is
approximately 30 %. However, most hepatic metastases from colorectal cancer were inoperable.
With the progress of chemotherapy, for example, the combination of the 5-Fu, leucovorin, and
oxaliplatin, some surgeons advocated that approximately 20% of inoperable liver metastases
will be converted to operable case, thus providing the long-term survival for patients. In
this study, we made a phase Ⅱ clinical trial regarding the use of the Folfox-4 regimens in
the neo-adjuvant treatment of inoperable hepatic metastases. Our aims is to evaluate the
tumor response rate for this regimen, the rate of resectability of liver metastases,
progression free survival and overall survival of patients. In addition, the difference
between the reports from Western and Oriental countries will be analyzed. We believe this
study will provide new perspectives regarding the most beneficial treatment modalities for
the patients with hepatic metastases from colorectal cancer.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Response rate and resectability after neoadjuvant therapy.
Jin-Tung Liang, M.D., Ph.D.
Department of Surgery, National Taiwan University Hospital, No.7, Chung-Shan South Road, Taipei, TAIWAN, R.O.C.
Taiwan: Department of Health